EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.7.1.20 | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol | compound displays very significant antimycobacterial activity, IC50 value 0.3 microM, but shows the highest cytotoxicity of the compounds tested. Compound only weakly inhibits in vitro adenosine kinase | Mycobacterium tuberculosis | |
2.7.1.20 | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[4-(1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3,4-diol | compound exhibits moderate antimycobacterial activity, IC50 value 15.6 microM, accompanied by preferentialinhibition of adenosine kinase and low cytotoxicity | Mycobacterium tuberculosis | |
2.7.1.20 | [(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl]methyl octadecyl hydrogen phosphate | octadecylphosphate prodrug designed as lipophilic derivatives with increased penetration through the mycobacterial cell wall, no antimycobacterial activity | Mycobacterium tuberculosis |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.7.1.20 | Mycobacterium tuberculosis | - |
- |
- |
EC Number | IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|---|
2.7.1.20 | 0.0088 | - |
pH not specified in the publication, temperature not specified in the publication | Mycobacterium tuberculosis | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol | |
2.7.1.20 | 0.78 | - |
pH not specified in the publication, temperature not specified in the publication | Mycobacterium tuberculosis | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[4-(1H-imidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3,4-diol |